Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
opioid |
| gptkbp:ATCCode |
V03AB15
|
| gptkbp:CASNumber |
156-75-0
|
| gptkbp:category |
phenols
secondary alcohols analgesics allyl compounds kappa-opioid receptor agonists morphinans mu-opioid receptor antagonists opioid antagonists tertiary amines |
| gptkbp:developedBy |
gptkb:Hoffmann-La_Roche
|
| gptkbp:discoveredBy |
1940s
|
| gptkbp:has_stereoisomer |
dextrallorphan
|
| gptkbp:hasMolecularFormula |
C17H23NO
|
| https://www.w3.org/2000/01/rdf-schema#label |
levallorphan
|
| gptkbp:isomerOf |
gptkb:levomethorphan
|
| gptkbp:IUPACName |
(−)-17-allyl-4,5α-epoxymorphinan-3-ol
|
| gptkbp:legalStatus |
prescription only (varies by country)
|
| gptkbp:mechanismOfAction |
mu-opioid receptor antagonist
kappa-opioid receptor agonist |
| gptkbp:molecularWeight |
257.37 g/mol
|
| gptkbp:notableFor |
adjunct to anesthesia
counteract opioid toxicity |
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201202
5362119 DB01343 |
| gptkbp:relatedTo |
gptkb:levomethorphan
gptkb:nalorphine gptkb:naloxone |
| gptkbp:routeOfAdministration |
intramuscular
subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
vomiting respiratory depression hallucinations dysphoria |
| gptkbp:UNII |
6U8X9A1E42
|
| gptkbp:used_to_reverse |
opioid overdose
opioid-induced respiratory depression |
| gptkbp:usedFor |
analgesic
opioid |
| gptkbp:bfsParent |
gptkb:Naltrexone
|
| gptkbp:bfsLayer |
6
|